Released May 6, 2021, before the open
10-Q filed May 7, 2021, 37 days after period end · 0001171843-21-003314
Q1 2021 · 10-Q
Revenue$26.99M$26.99M +13.5% vs Q1 2020−12.9% vs Q4 2020
Net Income-$669.00K-$669.00K N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.02-$0.02 N/M vs Q1 2020no prior Q4 2020 on file
Gross Profit$15,431,000+18.9%
Operating Income-$239,000N/M
Operating Cash Flow$1,037,000−63.9%
Free Cash Flowderived$886,000−66.3%
Margins · derived
Gross margin57.2%+2.6 pt vs Q1 2020
Operating margin-0.9%+12.9 pt vs Q1 2020
Net margin-2.5%+16.5 pt vs Q1 2020
What the release said
The release
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $26.99M | $23.77M | $28.20M | $26.76M |
| Net Income | -$669.00K | -$4.52M | -$2.37M | -$4.06M |
| EPS Diluted | -$0.02 | -$0.12 | -$0.06 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR